Quick Answer
Rallybio Corp reported Cash and Equivalents of $31.37 million for fiscal year 2025.
Rallybio Corp Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $31.37M | +125.7% |
| 2024 | $13.90M | -43.2% |
| 2023 | $24.49M | -57.0% |
| 2022 | $56.96M | -67.5% |
| 2021 | $175.33M | +25.0% |
| 2020 | $140.23M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $32.12M | +26.9% | +240.1% |
| June 30, 2025 | $9.45M | -43.3% | -36.1% |
| March 31, 2025 | $14.78M | -23.4% | +6.3% |
| December 31, 2024 | $13.90M | -43.2% | -45.1% |
| September 30, 2024 | $25.32M | +32.2% | +51.9% |
| June 30, 2024 | $16.67M | -48.8% | -13.6% |
| March 31, 2024 | $19.30M | -51.2% | -21.2% |
| December 31, 2023 | $24.49M | -57.0% | +27.9% |
- Rallybio Corp showed an increase of +125.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Rallybio Corp’s cash and equivalents has declined by 77.6% (from $140.23 million to $31.37 million).
- The most recent figure is from Rallybio Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: